These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21871176)

  • 21. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
    Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
    Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.
    Li X; Wu Y; Liu A; Tang X
    Biochem Biophys Res Commun; 2016 Sep; 477(4):768-773. PubMed ID: 27363334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.
    Zhang C; Meng W; Wang J; Lu Y; Hu G; Hu L; Ma J
    Cell Mol Neurobiol; 2017 Aug; 37(6):1021-1027. PubMed ID: 27757741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.
    Huang KT; Takano EA; Mikeska T; Byrne DJ; Dobrovic A; Fox SB
    Breast Cancer Res Treat; 2011 Nov; 130(1):319-29. PubMed ID: 21755341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.
    Ong DC; Ho YM; Rudduck C; Chin K; Kuo WL; Lie DK; Chua CL; Tan PH; Eu KW; Seow-Choen F; Wong CY; Hong GS; Gray JW; Lee AS
    Oncogene; 2009 Nov; 28(47):4189-200. PubMed ID: 19734946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
    Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
    Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Clofarabine-Based Combinations with Polyphenols Epigenetically Reactivate Retinoic Acid Receptor Beta, Inhibit Cell Growth, and Induce Apoptosis of Breast Cancer Cells.
    Lubecka K; Kaufman-Szymczyk A; Cebula-Obrzut B; Smolewski P; Szemraj J; Fabianowska-Majewska K
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer.
    Klebig C; Seitz S; Arnold W; Deutschmann N; Pacyna-Gengelbach M; Scherneck S; Petersen I
    Cancer Res; 2005 Jan; 65(2):394-400. PubMed ID: 15695379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of hypermethylation and reactivation of glutathione S-transferase pi 1 gene by curcumin in breast cancer cell line.
    Kumar U; Sharma U; Rathi G
    Tumour Biol; 2017 Feb; 39(2):1010428317692258. PubMed ID: 28222671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
    Shin H; Kim JH; Lee YS; Lee YC
    Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo.
    Li Y; Xu Z; Li B; Zhang Z; Luo H; Wang Y; Lu Z; Wu X
    Int J Oncol; 2014 Dec; 45(6):2576-86. PubMed ID: 25270964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
    Bagu ET; Miah S; Dai C; Spriggs T; Ogunbolude Y; Beaton E; Sanders M; Goel RK; Bonham K; Lukong KE
    Oncotarget; 2017 Feb; 8(7):11442-11459. PubMed ID: 28077797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer.
    Kang S; Kim B; Park SB; Jeong G; Kang HS; Liu R; Kim SJ
    Int J Oncol; 2013 Nov; 43(5):1659-65. PubMed ID: 24026393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MMP9 gene expression regulation by intragenic epigenetic modifications in breast cancer.
    Klassen LMB; Chequin A; Manica GCM; Biembengut IV; Toledo MB; Baura VA; de O Pedrosa F; Ramos EAS; Costa FF; de Souza EM; Klassen G
    Gene; 2018 Feb; 642():461-466. PubMed ID: 29162512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
    Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
    Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses.
    Minning C; Mokhtar NM; Abdullah N; Muhammad R; Emran NA; Ali SA; Harun R; Jamal R
    Int J Oncol; 2014 Nov; 45(5):1959-68. PubMed ID: 25175708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.
    Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.
    Liu J; Zhang X; Liu A; Zhang D; Su Y; Liu Y; You D; Yuan L; Kong X; Wang X; Sun P
    Oncotarget; 2016 Jun; 7(24):36755-36766. PubMed ID: 27191984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.